VTVT
vTv Therapeutics Inc. NASDAQ Listed Jul 30, 2015$35.04
+3.30%
vs $33.92
Mkt Cap $295.2M
52w Low $14.00
73.3% of range
52w High $42.72
50d MA $34.02
200d MA $31.52
P/E (TTM)
-10.9x
EV/EBITDA
—
P/B
4.6x
Debt/Equity
0.0x
ROE
-41.9%
P/FCF
-11.7x
RSI (14)
55.70
ATR (14)
$1.77
Beta
0.40
50d MA
$34.02
200d MA
$31.52
Avg Volume
44.3K
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
3980 Premier Drive · High Point, NC 27265 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | AMC | -0.98 | -0.58 | +40.8% | 35.02 | +9.8% | +0.2% | -4.0% | -1.3% | +14.6% | -3.8% | — |
| Nov 6, 2025 | AMC | -0.97 | -1.08 | -11.3% | 25.47 | -4.6% | +2.2% | +7.6% | +4.0% | +6.5% | +0.9% | — |
| Aug 12, 2025 | AMC | -0.85 | -0.92 | -8.2% | 14.49 | -3.4% | -3.2% | +9.1% | +0.9% | +0.5% | +0.0% | — |
| May 15, 2025 | AMC | -0.73 | -0.77 | -5.5% | 22.41 | -0.0% | -6.2% | +1.0% | -2.4% | -3.7% | -2.7% | — |
| Mar 20, 2025 | AMC | -0.87 | -0.55 | +36.8% | 17.61 | -5.1% | -5.5% | +4.4% | -1.0% | +0.1% | -0.3% | — |
| Nov 12, 2024 | AMC | -3.60 | -0.88 | +75.6% | 13.91 | -0.8% | +7.1% | +5.0% | +11.3% | -2.9% | -2.8% | — |
| Aug 8, 2024 | AMC | -3.20 | -0.81 | +74.7% | 13.49 | -1.9% | -1.8% | -1.9% | +1.4% | +1.0% | +1.4% | — |
| May 9, 2024 | AMC | -3.20 | -1.17 | +63.4% | 26.83 | -3.1% | -3.1% | -0.3% | +0.3% | -0.4% | +7.7% | — |
| Mar 13, 2024 | AMC | -2.80 | -1.67 | +40.4% | 16.04 | +0.0% | +6.3% | +5.6% | +11.8% | +3.9% | +27.6% | — |
| Nov 9, 2023 | AMC | -3.20 | -3.20 | +0.0% | 15.20 | -5.3% | -6.8% | +0.6% | -1.7% | +0.3% | +3.1% | — |
| Aug 11, 2023 | AMC | -0.07 | -2.80 | -3900.0% | 28.84 | -2.2% | +2.6% | -3.6% | -0.1% | -1.0% | -4.8% | — |
| May 11, 2023 | AMC | -3.20 | -2.40 | +25.0% | 35.60 | +0.0% | -5.5% | +2.1% | +4.8% | +5.2% | -1.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11 | BTIG | Maintains | Buy → Buy | — | $35.02 | $38.44 | +9.8% | +0.2% | -4.0% | -1.3% | +14.6% | -3.8% |
| Jan 27 | BTIG | Maintains | Buy → Buy | — | $33.86 | $34.44 | +1.7% | +0.4% | +0.1% | +0.3% | +3.7% | +8.2% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.72 | $36.48 | +5.1% | +3.7% | +1.8% | +2.3% | -1.3% | +2.4% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.49 | $14.00 | -3.4% | -3.2% | +9.1% | +0.9% | +0.5% | +0.0% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.60 | $36.40 | -3.2% | -4.8% | -6.1% | -4.5% | -10.3% | +8.6% |
| Aug 16 | Northland Capital Markets | Maintains | Outperform → Outperform | — | $54.80 | $52.40 | -4.4% | -11.7% | +6.6% | -5.4% | +0.0% | -5.7% |
| Feb 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $28.48 | $30.80 | +8.1% | +19.2% | -9.3% | -6.5% | +4.2% | +8.0% |
| Feb 10 | H.C. Wainwright | Maintains | Buy → Buy | — | $84.00 | $153.60 | +82.9% | +52.4% | -0.6% | -3.5% | -4.2% | -1.4% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $84.00 | $153.60 | +82.9% | +52.4% | -0.6% | -3.5% | -4.2% | -1.4% |
| May 30 | H.C. Wainwright | Maintains | Buy → Buy | — | $70.00 | $72.80 | +4.0% | +4.0% | +0.5% | -7.7% | +0.6% | -1.8% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $70.00 | $72.80 | +4.0% | +4.0% | +0.5% | -7.7% | +0.6% | -1.8% |
| May 5 | Northland Capital Markets | Upgrade | Market Perform → Outperform | — | — | — | — | — | — | — | — | — |
| Apr 10 | Stifel | Downgrade | Buy → Hold | — | $130.40 | $40.40 | -69.0% | -78.1% | -0.6% | +12.7% | -5.0% | +9.3% |
| Apr 10 | Piper Sandler | Downgrade | Overweight → Neutral | — | $130.40 | $40.40 | -69.0% | -78.1% | -0.6% | +12.7% | -5.0% | +9.3% |
| Apr 10 | Northland Securities | Downgrade | Outperform → Market Perform | — | $130.40 | $40.40 | -69.0% | -78.1% | -0.6% | +12.7% | -5.0% | +9.3% |
| Apr 9 | Northland Capital Markets | Downgrade | Outperform → Market Perform | — | $136.80 | $137.60 | +0.6% | -4.7% | -78.1% | -0.6% | +12.7% | -5.0% |
| Apr 9 | Piper Sandler | Downgrade | Overweight → Neutral | — | $136.80 | $137.60 | +0.6% | -4.7% | -78.1% | -0.6% | +12.7% | -5.0% |
| Apr 9 | Roth Capital | Downgrade | Buy → Neutral | — | $136.80 | $137.60 | +0.6% | -4.7% | -78.1% | -0.6% | +12.7% | -5.0% |
| Apr 9 | Seaport Global | Downgrade | Buy → Neutral | — | $136.80 | $137.60 | +0.6% | -4.7% | -78.1% | -0.6% | +12.7% | -5.0% |
| Apr 9 | Stifel | Downgrade | Buy → Hold | — | $136.80 | $137.60 | +0.6% | -4.7% | -78.1% | -0.6% | +12.7% | -5.0% |
| Mar 29 | Seaport Global | Maintains | Buy → Buy | — | $156.40 | $169.20 | +8.2% | +4.1% | -4.4% | +3.9% | -5.0% | -3.9% |
| Feb 8 | Northland Securities | Maintains | Outperform → Outperform | — | $270.40 | $282.00 | +4.3% | +0.9% | -4.8% | -4.9% | +3.2% | -0.3% |
| Sep 26 | H.C. Wainwright | Maintains | Buy → Buy | — | $286.80 | $289.20 | +0.8% | +0.8% | +0.1% | -0.1% | -1.1% | +0.6% |
| Dec 17 | Janney Capital | Maintains | Buy → Buy | — | $258.80 | $266.00 | +2.8% | -1.2% | +1.9% | +1.5% | +8.8% | +4.7% |
| Sep 4 | Canaccord Genuity | Maintains | Buy → Buy | — | $380.00 | $367.60 | -3.3% | -1.9% | +3.4% | -4.4% | -2.8% | +2.8% |
| Aug 24 | Piper Sandler | Maintains | Overweight → Overweight | — | $354.00 | $318.00 | -10.2% | -0.1% | -5.1% | +6.9% | -0.7% | +5.7% |
| Aug 24 | Stifel | Maintains | Buy → Buy | — | $354.00 | $318.00 | -10.2% | -0.1% | -5.1% | +6.9% | -0.7% | +5.7% |
No insider trades available.
8-K
vTv Therapeutics Inc. -- 8-K Filing
vTv Therapeutics entered into a sales agreement with TD Securities to conduct an at-the-market offering, providing the company with a potential capital-raising mechanism.
May 13
8-K
Unknown — 8-K Filing
vTv's $20M licensing deal and extended cash runway reduce dilution risk while Phase 3 trial completion approaches mid-2026, potentially supporting stock if efficacy data proves positive.
Mar 10
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
VTVT's real-world evidence from 48,000+ type 1 diabetes patients showing improved glycemic outcomes with technology adoption strengthens its competitive positioning and supports regulatory/reimbursement arguments for its diabetes management solutions.
Mar 10
8-K · 7.01
! Medium
vTv Therapeutics Inc. -- 8-K 7.01: Regulation FD Disclosure
vTv Therapeutics disclosed an investor presentation that may be updated periodically through future SEC filings, signaling ongoing communication with market participants about company developments.
Feb 26
8-K · 1.01
!! High
vTv Therapeutics Inc. -- 8-K 1.01: Material Agreement
vTv Therapeutics entered a $20 million agreement with Newsoara Biopharma, potentially expanding its pipeline or securing funding for development initiatives.
Feb 2
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 1
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Small Cap Core Fund | 3,926 | $156K | Mar 2026 |
Valuation
Market Cap
$295.2M
Enterprise Value
$206.2M
P/E (TTM)
-10.95x
Forward P/E
—
PEG Ratio
0.00x
P/B
4.58x
P/S
—
P/FCF
-11.69x
EV/EBITDA
—
Shares Out
8.4M
Financials (TTM)
Revenue
$0
Net Income
-$27.0M
EBITDA
-$32.8M
Free Cash Flow
-$25.3M
Op Cash Flow
-$25.3M
EPS Basic
$-3.20
EPS Diluted
$-3.20
EPS Forward
$-2.57
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$89.9M
Total Liab.
$25.5M
Total Equity
$64.4M
Cash
$88.9M
LT Debt
$0
Book Value/Sh
$7.65
Debt/Equity
0.00x
Current Ratio
13.54
Quick Ratio
13.54
Returns & Growth
ROE
-41.9%
ROA
-30.0%
ROIC
-39.4%
Rev Growth YoY
-100.0%
EPS Growth YoY
—
Price Returns
2W
-13.2%
1M
+3.4%
3M
-12.6%
6M
+24.9%
12M
+109.9%
Technicals
52W High
$42.72
52W Low
$14.00
50d MA
$34.02
200d MA
$31.52
RSI (14)
55.70
ATR (14)
$1.77
Beta
0.40
Avg Volume
44K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$51.33
High
$58.00
Low
$47.00
Median
$49.00
Data updated apr 27, 2026 8:30am
· Source: financialmodelingprep.com